Skip Navigation


JAC Advance Access originally published online on August 13, 2003
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
52/3/500    most recent
dkg373v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Piddock, L. J. V.
Right arrow Articles by Webber, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Piddock, L. J. V.
Right arrow Articles by Webber, M. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Journal of Antimicrobial Chemotherapy (2003) 52, 500-502
© 2003 The British Society for Antimicrobial Chemotherapy

Activity of faropenem and imipenem for ciprofloxacin-resistant bacteria

Laura J. V. Piddock*, M. M. Johnson and Mark A. Webber

Antimicrobial Agents Research Group, Division of Immunity and Infection, University of Birmingham, Birmingham B15 2TT, UK

Received 28 March 2003; returned 22 April 2003; revised 13 June 2003; accepted 18 June 2003

Aim: To determine whether an association exists between ciprofloxacin and faropenem resistance in bacteria including multiply drug-resistant isolates.

Methods: The MICs were determined for 150 fluoroquinolone-resistant bacteria, plus 20 nalidixic acid-resistant strains of Salmonella enterica serovar Typhimurium.

Results: Faropenem was very active against Escherichia coli and Streptococcus pneumoniae, but 5/31 Staphylococcus aureus and 2/26 Bacteroides fragilis required >=16 mg/L for inhibition. Of 30 multiply drug-resistant isolates with a phenotype suggestive of enhanced efflux, only for one strain (a Bacteroides fragilis) was the faropenem MIC higher than that associated with the other isolates of the same species.

Conclusions: Faropenem was in general as active as imipenem. There was no association between resistance to ciprofloxacin and faropenem or imipenem resistance.

Keywords: carbapenem, fluoroquinolone, MIC

* Corresponding author. Tel: +44-121-414-6966; Fax: +44-121-414-3599; E-mail: l.j.v.piddock{at}bham.ac.uk


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Med MicrobiolHome page
M. R. Capoor, D. Nair, J. Posti, S. Singhal, M. Deb, P. Aggarwal, and P. Pillai
Minimum inhibitory concentration of carbapenems and tigecycline against Salmonella spp.
J. Med. Microbiol., March 1, 2009; 58(3): 337 - 341.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.